1. Home
  2. ALVR vs SHLT Comparison

ALVR vs SHLT Comparison

Compare ALVR & SHLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALVR
  • SHLT
  • Stock Information
  • Founded
  • ALVR 2013
  • SHLT 1987
  • Country
  • ALVR United States
  • SHLT Israel
  • Employees
  • ALVR N/A
  • SHLT N/A
  • Industry
  • ALVR Biotechnology: Biological Products (No Diagnostic Substances)
  • SHLT Business Services
  • Sector
  • ALVR Health Care
  • SHLT Consumer Discretionary
  • Exchange
  • ALVR Nasdaq
  • SHLT Nasdaq
  • Market Cap
  • ALVR 87.7M
  • SHLT 63.6M
  • IPO Year
  • ALVR 2020
  • SHLT N/A
  • Fundamental
  • Price
  • ALVR $0.94
  • SHLT $2.74
  • Analyst Decision
  • ALVR Sell
  • SHLT Strong Buy
  • Analyst Count
  • ALVR 5
  • SHLT 1
  • Target Price
  • ALVR $1.00
  • SHLT $11.00
  • AVG Volume (30 Days)
  • ALVR 155.6K
  • SHLT 3.2K
  • Earning Date
  • ALVR 11-04-2024
  • SHLT 09-26-2024
  • Dividend Yield
  • ALVR N/A
  • SHLT N/A
  • EPS Growth
  • ALVR N/A
  • SHLT N/A
  • EPS
  • ALVR N/A
  • SHLT N/A
  • Revenue
  • ALVR N/A
  • SHLT $55,939,000.00
  • Revenue This Year
  • ALVR N/A
  • SHLT N/A
  • Revenue Next Year
  • ALVR N/A
  • SHLT N/A
  • P/E Ratio
  • ALVR N/A
  • SHLT N/A
  • Revenue Growth
  • ALVR N/A
  • SHLT N/A
  • 52 Week Low
  • ALVR $0.58
  • SHLT $2.60
  • 52 Week High
  • ALVR $2.49
  • SHLT $10.44
  • Technical
  • Relative Strength Index (RSI)
  • ALVR 69.10
  • SHLT 37.68
  • Support Level
  • ALVR $0.74
  • SHLT $2.64
  • Resistance Level
  • ALVR $0.91
  • SHLT $2.89
  • Average True Range (ATR)
  • ALVR 0.06
  • SHLT 0.12
  • MACD
  • ALVR 0.01
  • SHLT 0.01
  • Stochastic Oscillator
  • ALVR 94.50
  • SHLT 23.92

About ALVR AlloVir Inc.

AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.

About SHLT SHL Telemedicine Ltd

SHL Telemedicine Ltd develops and markets personal telemedicine solutions. It consists of the transmission of medical data by an individual, from a remote location to a medical call center through telecommunication networks. The company offers solutions to subscribing patients, health insurance companies, hospitals, clinics, and physicians. It provides healthcare professional solutions to patients suffering from congestive heart failure, chronic obstructive pulmonary disease, and readmission solutions for reducing heart-related readmissions. In addition, consumer solutions include cardiac monitoring services. The company's geographical segments Israel, Europe, and the rest of the world, out of which majority revenue comes from Israel.

Share on Social Networks: